2017 - 2018 LEGISLATURE
May 8, 2017 - Introduced by Representatives Horlacher, Bernier, Allen,
Billings, Edming, Hutton, Jacque, Katsma, Kremer, Mursau, Novak,
Nygren, Ott, Petryk, Ripp, Sinicki, Skowronski, Spiros and Tittl,
cosponsored by Senators Harsdorf, Cowles, Moulton, Olsen, Petrowski,
Ringhand, Stroebel and Wanggaard. Referred to Committee on Health.
1An Act to renumber and amend
961.23 (4), 961.235 (1) and 961.235 (3); to
961.235 (2); and to create
961.23 (4) (b), 961.235 (1) (b) and (c) and 3
961.235 (3m), (4), (5), (7) and (8) of the statutes; relating to: tracking the sale
4of pseudoephedrine products.
Analysis by the Legislative Reference Bureau
This bill requires the implementation of an electronic system for recording,
tracking, and blocking the illegal sale of pseudoephedrine products and makes
certain other changes to the pseudoephedrine sale process.
Current law requires that sellers of pseudoephedrine products record the name
and address of the purchaser and the name and quantity of the pseudoephedrine
product being sold in either paper or electronic format, and requires the purchaser
to present an identification card containing the purchaser's photograph. At the time
of sale, both the seller, or a pharmacist supervising the seller, and the purchaser
must also sign a record of the transaction. Under the bill, the purchaser must present
an identification card containing the purchaser's photograph, and the seller must
record the identification type and, if applicable, the identification number, and the
date and time of the sale, in addition to the information that is currently gathered,
and all records must be kept in electronic format.
Under the bill, prior to completing a pseudoephedrine sale, the seller must
electronically submit the sale information to the National Precursor Log Exchange,
which is a real-time electronic tracking system that is available at no cost to the
sellers. The system uses the information to generate a real-time notification, called
a stop sale alert, that notifies the seller if completing the sale would cause the
purchaser to be in violation of the quantity limits currently in place on
nonprescription pseudoephedrine purchases. The system will contain an override
function that the seller may use in emergencies, the use of which is recorded by the
system. The system must provide real-time access to the records for law
enforcement purposes. The tracking requirements do not apply to pseudoephedrine
sales pursuant to a valid prescription.
The people of the state of Wisconsin, represented in senate and assembly, do
enact as follows:
961.23 (4) of the statutes is renumbered 961.23 (4) (a) and amended 2
(a) Any person purchasing such a substance that is not a
shall, at the time of purchase, present to the seller that 5
person's correct name, and
address, and, if the person is purchasing a
6pseudoephedrine product, an identification card containing the person's photograph
The seller shall record the name and address and the name and quantity of the 8
product sold. The purchaser and either the seller or, if the substance is a
9pseudoephedrine product and is being sold by a person who is not a registered
10pharmacist, the pharmacist supervising
the seller shall sign the record of this the 11
transaction. The giving of a false name or false address by the purchaser shall be 12
prima facie evidence of a violation of s. 961.43 (1) (a).
961.23 (4) (b) of the statutes is created to read:
(b) Any person purchasing such a substance that is a 15
pseudoephedrine product shall, at the time of purchase, present to the seller that 16
person's correct name, address, and an identification card containing the person's 17
photograph. The seller shall record the name, date of birth, and address of the 18
purchaser; the name and quantity measured in grams of pseudoephedrine contained
in the product purchased; the date and time purchased; and the purchaser 2
identification type and number, such as driver's license state and number. The 3
purchaser and either the seller or, if the pseudoephedrine product is being sold by a 4
person who is not a registered pharmacist, the pharmacist supervising the seller 5
shall sign the record of the transaction. The giving of a false name or false address 6
by the purchaser shall be prima facie evidence of a violation of s. 961.43 (1) (a).
961.235 (1) of the statutes is renumbered 961.235 (1) (intro.) and 8
amended to read:
(intro.) In this section, “
of pseudoephedrine sales" means records required under s. 961.23 11
with respect to the sale of a pseudoephedrine product.
961.235 (1) (b) and (c) of the statutes are created to read:
(b) “Stop sale alert” means a real-time notification to a seller of 14
pseudoephedrine products that completion of the sale would result in the purchaser 15
violating the pseudoephedrine quantity limits set forth in s. 961.23 (6).
(c) “System” means the National Precursor Log Exchange (NPLEx) system, 17
which is an electronic pseudoephedrine sales tracking system that is capable of 18
generating stop sale alerts, and that is installed, operated, and maintained free of 19
any one-time or recurring charge to the seller or to the state.
961.235 (2) of the statutes is amended to read:
Records of pseudoephedrine sales
be kept in either a
electronic format and shall be maintained by the pharmacy for at least 2 23
years. Except as provided in sub. (3) subs. (6) and (7)
, only a pharmacist may have 24
access to records of pseudoephedrine sales and information contained in those 25
961.235 (3) of the statutes is renumbered 961.235 (6) and amended 2
A pharmacist shall make records required under s. 961.23 (4) (b) 4
available to a law enforcement officer who requests them. Law enforcement officers 5
may make those records available to other persons or redisclose information from 6
those records to other persons only in connection with a criminal investigation or 7
prosecution under this chapter.
961.235 (3m), (4), (5), (7) and (8) of the statutes are created to read:
Except as provided in sub. (4), a seller shall electronically submit 10
records of pseudoephedrine sales to the system before completing a sale of a 11
nonprescription pseudoephedrine product.
If a seller who is attempting to complete a sale of a nonprescription 13
pseudoephedrine product experiences mechanical or electronic failure of the system 14
and is unable to comply with the requirement in sub. (3m), the seller may, subject to 15
the requirement under s. 961.23 (4) (b), complete the sale without complying with the 16
requirement under sub. (3m). The seller shall maintain a written log or an 17
alternative electronic record-keeping mechanism until such time as the seller is able 18
to comply with the requirement.
A seller may not complete a sale of a nonprescription pseudoephedrine 20
product if the system generates a stop sale alert unless the seller has a reasonable 21
fear of imminent bodily harm if he or she does not complete the sale. The seller may 22
use the system's override function to complete the sale if he or she has a reasonable 23
fear of imminent bodily harm.
The system shall provide real-time access through an online portal to 25
records of pseudoephedrine sales submitted under sub. (3m) to the department of
justice and to law enforcement officers in the state. Law enforcement officers may 2
make those records available to other persons or redisclose information from those 3
records to other persons only in connection with a criminal investigation or 4
prosecution under this chapter.
Absent negligence, wantonness, recklessness, or deliberate misconduct, 6
any seller utilizing the system in accordance with this section shall not be civilly 7
liable as a result of any act or omission in carrying out the duties required by this 8
section and shall be immune from liability to any third party unless the seller has 9
violated any provision of this section in relation to a claim brought for such a 10
This act takes effect on the first day of the 6th month beginning after 13